|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
17 October 2012 |
|
Main ID: |
NCT00141999 |
|
Date of registration:
|
01/09/2005 |
|
Primary sponsor: |
|
|
Public title:
|
Response to Booster Doses of Hepatitis B Vaccine in Children and Adolescents
|
|
Scientific title:
|
An Evaluation of Long-Term Protection Against Hepatitis B Virus Infection: Response of Alaska Native Children and Adolescents Who Received the Primary Recombinant Hepatitis B Vaccine Series Beginning at Birth to an Additional Dose of Vaccine |
|
Date of first enrolment:
|
May 2001 |
|
Target sample size:
|
400 |
|
Recruitment status: |
Completed |
|
URL:
|
http://clinicaltrials.gov/show/NCT00141999 |
|
Study type:
|
Observational |
|
Study design:
|
Time Perspective: Prospective
|
|
|
Countries of recruitment
|
|
United States
| | | | | | | |
|
Contacts
|
|
Name:
|
Anthony Fiore, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Centers for Disease Control and Prevention |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
Received 3 doses of hepatitis B vaccine during infancy, beginning at birth
Exclusion Criteria:
Mother HBsAg-positive immunosuppressed
Age minimum:
5 Years
Age maximum:
14 Years
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Hepatitis
|
|
Intervention(s)
|
|
Biological: hepatitis B vaccine
|
|
Secondary ID(s)
|
|
CDC-NCID-2998
|
|
U50/CCU022279
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|